Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of TEDAVIR versus Descovy + Tivicay under fasting in healthy Thai subjects
TCTR20220510003Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Government Pharmaceutical Organization. Primary endpoint: Primary pharmacokinetic bioequivalence parameters. Planned start Jul 2022; status: not yet recruiting.
02
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20220510003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220510003.